Trial · NCT03884842
Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
NCT03884842, Phase 3, Completed, McMaster University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma. Trials, record NCT03884842. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03884842
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
- NCT number
- NCT03884842
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 24 participants, actual
- Lead sponsor
- McMaster University
- Conditions
- Asthma
- Interventions
- Dupilumab/Dupixent, Placebo
- First posted
- 2019-03-21
- Last updated
- 2023-01-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients that achieve at least one doubling dose improvement in PC20 methacholine and/or a 50% reduction in FEV1 reversibility after bronchodilator. | Between screening (week -4) and week 16. | For patients that can undergo a methacholine challenge, one doubling dose improvement in PC20 methacholine. For those that cannot undergo a methacholine challenge a 50% reduction in FEV1 reversibility. |
| Secondary | Change in geometric mean PC20 methacholine. | Between screening (week -4) and week 16. | Change in PC20 between screening and week 16. |
| Secondary | Change in FEV1 reversibility. | Between randomization (week 0) and week 16. | Change in FEV1 % reversibility (pre/post bronchodilator) between randomization and end of treatment. |
| Secondary | Change in sputum eosinophil percentage (%) | Between randomization (week 0) and week 16. | Change in sputum eosinophil percentage between randomization and end of treatment |
| Secondary | Change in blood eosinophil count | Between randomization (week 0) and week 16. | Change in blood eosinophil count levels between randomization and end of treatment |
| Secondary | Change in fraction of exhaled nitric oxide (FeNO) | Between randomization (week 0) and week 16. | Change in FeNO values parts per billion (ppb) from randomization and end of treatment. |
| Secondary | Change in FEV1 (pre-bronchodilator) | Between randomization (week 0) and week 16. | Change in pre-bronchodilator FEV1 values (in litres) between randomization and end of treatment. |
| Secondary | Change in Asthma Control Questionnaire-5 (ACQ-5) | Between randomization (week 0) and week 16. | Change in ACQ scores between randomization and end of treatment. |
| Secondary | Change in Asthma Control Questionnaire-5 (AQLQ) | Between randomization (week 0) and week 16. | Change in AQLQ scores between randomization and end of treatment. |
| Secondary | Change in Asthma Control Test (ACT) | Between randomization (week 0) and week 16. | Change in ACT scores between randomization and end of treatment. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03884842
GET https://conductscience.org/api/trials/v1/NCT03884842/registered